• Users Online: 73
  • Print this page
  • Email this page
Year : 2021  |  Volume : 8  |  Issue : 1  |  Page : 17-21

Update on promising biomarkers for multiple sclerosis

1 Department of Medical Elementology and Toxicology, Jamia Hamdard University, Delhi, India
2 Centre for Biotechnology and Bioinformatics, Dibrugarh University, Assam, India
3 Department of Biotechnology, Pandu College, Guwahati, Assam, India

Correspondence Address:
Faizan Ahmad
Qno/B730, Hec Sector 2, Dhurwa, Ranchi, Jharkhand
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/jnbs.jnbs_40_20

Rights and Permissions

Multiple sclerosis (MS) is a chronic autoimmune disease, in which there is chronic inflammation leading to neurodegeneration and demyelination. To detect MS at an early stage is impossible as it includes environmental factors and genetic factors as it varies from person to person. There are various methodologies that have been developed for the treatment of this disease; however, several complications as well as obstacles have been seen which are yet to be resolved. This review describes the biomarker for MS including microRNA and vaccine as a biomarker. Some of the drugs which are under phase II clinical trials are also discussed here. Testing and continuous validation is required for improvement where MS biomarkers are brought into clinical settings.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded293    
    Comments [Add]    

Recommend this journal